272 related articles for article (PubMed ID: 37534217)
21. Oxidative stress in pituitary neuroendocrine tumors: Affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy.
Zhou Y; Zhang A; Fang C; Yuan L; Shao A; Xu Y; Zhou D
CNS Neurosci Ther; 2023 Oct; 29(10):2744-2759. PubMed ID: 37341156
[TBL] [Abstract][Full Text] [Related]
22. DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors.
García-Martínez A; Sottile J; Sánchez-Tejada L; Fajardo C; Cámara R; Lamas C; Barberá VM; Picó A
J Clin Endocrinol Metab; 2019 Apr; 104(4):1272-1282. PubMed ID: 30423170
[TBL] [Abstract][Full Text] [Related]
23. Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors.
Chen Y; Gao H; Liu Q; Xie W; Li B; Cheng S; Guo J; Fang Q; Zhu H; Wang Z; Wang J; Li C; Zhang Y
Aging (Albany NY); 2020 Dec; 13(1):1422-1439. PubMed ID: 33472171
[TBL] [Abstract][Full Text] [Related]
24. Transcriptomic analysis identifies a tumor subtype mRNA classifier for invasive non-functioning pituitary neuroendocrine tumor diagnostics.
Bao X; Wang G; Yu S; Sun J; He L; Zhao H; Ma Y; Wang F; Wang X; Wang R; Yu J
Theranostics; 2021; 11(1):132-146. PubMed ID: 33391466
[No Abstract] [Full Text] [Related]
25. Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients.
Guaraldi F; Morandi L; Zoli M; Mazzatenta D; Righi A; Evangelisti S; Ambrosi F; Tonon C; Giannini C; Lloyd RV; Asioli S
Clin Endocrinol (Oxf); 2022 Dec; 97(6):763-772. PubMed ID: 36161330
[TBL] [Abstract][Full Text] [Related]
26. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
Luo M; Tang R; Wang H
J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134
[TBL] [Abstract][Full Text] [Related]
27. Lysine Methyltransferase 5A Promotes the Progression of Growth Hormone Pituitary Neuroendocrine Tumors through the Wnt/β-Catenin Signaling Pathway.
Li J; Song H; Chen T; Zhang S; Zhang C; Ma C; Zhang L; Wang T; Qian Y; Deng X
Neuroendocrinology; 2024; 114(6):589-601. PubMed ID: 38565081
[TBL] [Abstract][Full Text] [Related]
28. Single-cell transcriptomic analysis reveals tumor cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumors.
Yan N; Xie W; Wang D; Fang Q; Guo J; Chen Y; Li X; Gong L; Wang J; Guo W; Zhang X; Zhang Y; Gu J; Li C
Genome Med; 2024 Jan; 16(1):2. PubMed ID: 38167466
[TBL] [Abstract][Full Text] [Related]
29. TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT.
Yao H; Xie W; Dai Y; Liu Y; Gu W; Li J; Wu L; Xie J; Rui W; Ren B; Xue L; Cheng Y; Lin S; Li C; Tang H; Wang Y; Lou M; Zhang X; Hu R; Shang H; Huang J; Wu ZB
Neuro Oncol; 2022 Aug; 24(8):1286-1297. PubMed ID: 35218667
[TBL] [Abstract][Full Text] [Related]
30. LINC00887 Acts as an Enhancer RNA to Promote Medullary Thyroid Carcinoma Progression by Binding with FOXQ1.
Liu D; Wang W; Wu Y; Qiu Y; Zhang L
Curr Cancer Drug Targets; 2024; 24(5):519-533. PubMed ID: 38804344
[TBL] [Abstract][Full Text] [Related]
31. Aggressive nonfunctioning pituitary neuroendocrine tumors.
Portovedo S; Neto LV; Soares P; Carvalho DP; Takiya CM; Miranda-Alves L
Brain Tumor Pathol; 2022 Oct; 39(4):183-199. PubMed ID: 35725837
[TBL] [Abstract][Full Text] [Related]
32. Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors.
Cui Y; Li C; Jiang Z; Zhang S; Li Q; Liu X; Zhou Y; Li R; Wei L; Li L; Zhang Q; Wen L; Tang F; Zhou D
Neuro Oncol; 2021 Nov; 23(11):1859-1871. PubMed ID: 33908609
[TBL] [Abstract][Full Text] [Related]
33. DCP1A is an unfavorable prognostic-related enhancer RNA in hepatocellular carcinoma.
Wu H; Zhang J; Bai Y; Zhang S; Zhang Z; Tong W; Han P; Fu B; Zhang Y; Shen Z
Aging (Albany NY); 2021 Oct; 13(19):23020-23035. PubMed ID: 34609335
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Ability of Enhancer RNAs in Metastasis of Non-Small Cell Lung Cancer.
Liu J; Jia J; Wang S; Zhang J; Xian S; Zheng Z; Deng L; Feng Y; Zhang Y; Zhang J
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807355
[TBL] [Abstract][Full Text] [Related]
35. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
36. Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors.
Kara M; Tokat F; Pamir MN; Danyeli AE
Endocr Pathol; 2020 Jun; 31(2):166-173. PubMed ID: 32157655
[TBL] [Abstract][Full Text] [Related]
37. Neuropathology of Pituitary Adenomas and Sellar Lesions.
Kobalka PJ; Huntoon K; Becker AP
Neurosurgery; 2021 Apr; 88(5):900-918. PubMed ID: 33476394
[TBL] [Abstract][Full Text] [Related]
38. Identification of key eRNAs for intervertebral disc degeneration by integrated multinomial bioinformatics analysis.
Li Y; Huang R; Ye J; Han X; Meng T; Song D; Yin H
BMC Musculoskelet Disord; 2024 May; 25(1):356. PubMed ID: 38704519
[TBL] [Abstract][Full Text] [Related]
39. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
[TBL] [Abstract][Full Text] [Related]
40. Co-occurrence of Pituitary Neuroendocrine Tumors (PitNETs) and Tumors of the Neurohypophysis.
Saeger W; von Schöning J; Flitsch J; Jautzke G; Bergmann M; Hagel C; Knappe UJ
Endocr Pathol; 2021 Dec; 32(4):473-479. PubMed ID: 34129177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
